A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

Inclusion Criteria:

- Between 18 and 55 years of age inclusive, at the time of signing the informed consent.

- Healthy as determined by the Investigator or medically qualified designee based on a
medical evaluation including medical history, physical examination, laboratory tests
and cardiac monitoring.

- A subject with a clinical abnormality or laboratory parameter(s) which is/are not
specifically listed in the inclusion or exclusion criteria, and outside the reference
range for the population being studied, may be included only if the Investigator in
consultation with the medical monitor, if required, agree and document that the
finding is unlikely to introduce additional risk factors and will not interfere with
the study procedures.

- A creatinine clearance (CLcr) > 80 milliliter per minute (mL/min) as determined by
Cockcroft-Gault equation: CLcr = (140 minus age) multiplied by weight divided by (72
multiplied by serum creatinine) (times 0.85 if female) where age is in years, weight
in kilogram (kg), and serum creatinine is in units of milligram per deciliter (mg/dL).

- Body weight >=50.0 kg (110 pounds [lbs.]) for men and >=45.0 kg (99 lbs) for women and
body mass index (BMI) within the range 18.5 to 31.0 kg/meter (m)^2 (inclusive).

- Males or females.

- A female subject is eligible to participate if she is not pregnant (as confirmed by a
negative serum human chorionic gonadotrophin [hCG] test), not lactating, and of
non-reproductive potential which is defined as:

Reproductive potential:

There is no definitive drug-drug interaction (DDI) information with GSK2838232 and an
interaction with oral contraceptives is possible, so other (barrier, inter-uterine device
etc.) methods of contraception will be required. Females of reproductive potential may only
be enrolled if they are using two forms of complementary contraception, which must include
at least one barrier method. They will be counseled on safer sex practices. Fertile
females, who have an established, long-term lifestyle of sexual abstinence, or only same
sex partners, require no other means of birth control.

Non-reproductive potential:

- Pre-menopausal females with one of the following: Documented tubal ligation;
documented hysteroscopic tubal occlusion procedure with follow-up confirmation of
bilateral tubal occlusion; hysterectomy; documented Bilateral Oophorectomy.

- Postmenopausal defined as 12 months of spontaneous amenorrhea in questionable cases a
blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels
consistent with menopause. Females on hormone replacement therapy (HRT) must
discontinue HRT to allow confirmation of post-menopausal status prior to study
enrolment.

- Male subjects with female partners of child bearing potential must comply with
the following contraception requirements from the time of first dose of study
medication until one week after the last dose of study medication.

- Vasectomy with documentation of azoospermia.

- Male condom plus partner use of one of the contraceptive options below: Contraceptive
subdermal implant with a <1 percent rate of failure per year; intrauterine device or
intrauterine system with a <1 percent rate of failure per year; oral contraceptive,
either combined or progestogen alone or injectable progestogen; contraceptive vaginal
ring; percutaneous contraceptive patches.

- Capable of giving signed informed consent.

Exclusion Criteria:

- ALT >1.5 times upper limit of normal (ULN)

- Bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin
is fractionated and direct bilirubin <35 percent).

- Current or chronic history of liver disease, or known hepatic or biliary
abnormalities.

- Subjects who have asthma or a history of asthma.

- Medical history of cardiac arrhythmias or cardiac disease or a family or personal
history of long QT syndrome.

- Unable to refrain from the use of prescription or non-prescription drugs, including
vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or
14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is
longer) prior to the first dose of study medication, unless in the opinion of the
Investigator and GlaxoSmithKline medical monitor, the medication will not interfere
with the study procedures or compromise participant safety.

- History of regular alcohol consumption (within 6 months prior to screening or unable
to refrain from alcohol use from 5 days prior to admission through the last blood
sample collected) defined as:

• For United States sites: an average weekly intake of >14 drinks for males or >7
drinks for females. One drink is equivalent to 12 gram of alcohol: 12 ounces (360 mL)
of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled
spirits.

- Regular use of tobacco- or nicotine- containing products within 6 months prior to
screening. Unable to refrain from smoking from the Screening Visit through the last
blood sample collected. As confirmed by a urine cotinine test.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or medical
monitor, contraindicates their participation.

- Presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C virus (HCV)
test result at screening or within 3 months prior to first dose of study treatment.

- Screening or Baseline cardiac troponin I greater than the 99 percent cutoff (>0.045
nanogram [ng]/mL by the Dimension Vista cTnI assay) for a given assay.

- A positive pre-study drug/alcohol screen.

- A positive test for human immunodeficiency virus (HIV) antibody.

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within 56 days.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.

- Exclusion Criteria for 24-hour Screening Holter:

- Any symptomatic arrhythmia (except isolated extra systoles).

- Sustained cardiac arrhythmias (such as atrial fibrillation or flutter,
supraventricular tachycardia (>= 10 consecutive beats), complete heart block).

- Non-sustained or sustained ventricular tachycardia (defined as >=3 consecutive
ventricular ectopic beats).

- Any conduction abnormality (including but not specific to left or right
incomplete or complete bundle branch block, atrioventricular (AV) block [2nd
degree or higher], Wolff Parkinson White (WPW) syndrome etc.).

- Sinus Pauses >3 seconds.

- 300 or more supraventricular ectopic beats in 24 hours.

- 250 or more ventricular ectopic beats in 24 hours.

- Any clinically significant abnormal echocardiogram finding.

- Exclusion criteria for screening ECG (a single repeat is allowed for eligibility
determination):

- Heart rate <45 or >100 beats per minute (bpm) for males; <50 or >100 bpm for
females

- PR interval <120 or >220 milliseconds (msec)

- QRS duration <70 or >120 msec

- QTc interval (Fridericia's) >450 msec

- Evidence of previous myocardial infarction (does not include ST segment changes
associated with re-polarization).

- Any conduction abnormality (including but not specific to left or right complete
bundle branch block, AV block [2nd degree or higher], WPW syndrome).

- Sinus Pauses >3 seconds.

- Any significant arrhythmia which, in the opinion of the Investigator or GSK
medical monitor, will interfere with the safety for the individual subject.

- Non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular
ectopic beats).